Entry - #611895 - AMYOTROPHIC LATERAL SCLEROSIS 9; ALS9 - OMIM
# 611895

AMYOTROPHIC LATERAL SCLEROSIS 9; ALS9


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
14q11.2 Amyotrophic lateral sclerosis 9 611895 3 ANG 105850
Phenotypic Series
 

Amyotrophic lateral sclerosis - PS105400 - 40 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.22 Amyotrophic lateral sclerosis 10, with or without FTD AD 3 612069 TARDBP 605078
1p36.22 Frontotemporal lobar degeneration, TARDBP-related AD 3 612069 TARDBP 605078
2p13.3 Amyotrophic lateral sclerosis 26 with or without frontotemporal dementia AD 3 619133 TIA1 603518
2p13.1 {Amyotrophic lateral sclerosis, susceptibility to} AD, AR 3 105400 DCTN1 601143
2q33.1 Amyotrophic lateral sclerosis 2, juvenile AR 3 205100 ALS2 606352
2q34 Amyotrophic lateral sclerosis 19 AD 3 615515 ERBB4 600543
2q35 Amyotrophic lateral sclerosis 22 with or without frontotemporal dementia AD 3 616208 TUBA4A 191110
3p11.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 AD 3 600795 CHMP2B 609512
4q33 {Amyotrophic lateral sclerosis, susceptibility to, 24} AD 3 617892 NEK1 604588
5q31.2 Amyotrophic lateral sclerosis 21 AD 3 606070 MATR3 164015
5q35.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 AD 3 616437 SQSTM1 601530
6q21 Amyotrophic lateral sclerosis 11 AD 3 612577 FIG4 609390
8q22.3 Amyotrophic lateral sclerosis 28 AD 3 620452 LRP12 618299
9p21.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 AD 3 105550 C9orf72 614260
9p13.3 ?Amyotrophic lateral sclerosis 16, juvenile AR 3 614373 SIGMAR1 601978
9p13.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 6 AD 3 613954 VCP 601023
9q22.31 Amyotrophic lateral sclerosis 27, juvenile AD 3 620285 SPTLC1 605712
9q34.13 Amyotrophic lateral sclerosis 4, juvenile AD 3 602433 SETX 608465
10p13 Amyotrophic lateral sclerosis 12 with or without frontotemporal dementia AD, AR 3 613435 OPTN 602432
10q22.3 Amyotrophic lateral sclerosis 23 AD 3 617839 ANXA11 602572
12q13.12 {Amyotrophic lateral sclerosis, susceptibility to} AD, AR 3 105400 PRPH 170710
12q13.13 Amyotrophic lateral sclerosis 20 AD 3 615426 HNRNPA1 164017
12q13.3 {Amyotrophic lateral sclerosis, susceptibility to, 25} AD 3 617921 KIF5A 602821
12q14.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 AD 3 616439 TBK1 604834
12q24.12 Spinocerebellar ataxia 2 AD 3 183090 ATXN2 601517
12q24.12 {Amyotrophic lateral sclerosis, susceptibility to, 13} AD 3 183090 ATXN2 601517
14q11.2 Amyotrophic lateral sclerosis 9 3 611895 ANG 105850
15q21.1 Amyotrophic lateral sclerosis 5, juvenile AR 3 602099 SPG11 610844
16p13.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 5 AD 3 619141 CCNF 600227
16p11.2 Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia 3 608030 FUS 137070
16q12.1 ?Frontotemporal dementia and/or amyotrophic lateral sclerosis 8 AD 3 619132 CYLD 605018
17p13.2 Amyotrophic lateral sclerosis 18 3 614808 PFN1 176610
18q21 Amyotrophic lateral sclerosis 3 AD 2 606640 ALS3 606640
20p13 Amyotrophic lateral sclerosis 7 2 608031 ALS7 608031
20q13.32 Amyotrophic lateral sclerosis 8 AD 3 608627 VAPBC 605704
21q22.11 Amyotrophic lateral sclerosis 1 AD, AR 3 105400 SOD1 147450
22q11.23 Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 AD 3 615911 CHCHD10 615903
22q12.2 {?Amyotrophic lateral sclerosis, susceptibility to} AD, AR 3 105400 NEFH 162230
Xp11.21 Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia XLD 3 300857 UBQLN2 300264
Not Mapped Amyotrophic lateral sclerosis, juvenile, with dementia AR 205200 ALSDC 205200

TEXT

A number sign (#) is used with this entry because of evidence that amyotrophic lateral sclerosis-9 (ALS9) is caused by heterozygous mutation in the angiogenin gene (ANG; 105850) on chromosome 14q11.

For a general phenotypic description and a discussion of genetic heterogeneity of amyotrophic lateral sclerosis, see ALS1 (105400).


Clinical Features

Van Es et al. (2009) reported a 4-generation family with autosomal dominant ALS due to ANG mutation. Affected individuals had classic signs of the disorder, including progressive upper and lower motor neuron loss affecting the limbs, but 1 patient presented with parkinsonism and later developed signs of frontotemporal dementia. One obligate carrier did not develop the disease by age 75, indicating incomplete penetrance.


Mapping

Hayward et al. (1999) and Greenway et al. (2004) identified chromosome 14q11.2 as a candidate region for ALS in Irish and Scottish populations.


Molecular Genetics

Greenway et al. (2004) reported an association between ALS and a synonymous SNP in the ANG gene (rs11701) in an Irish population. Among in 1,629 individuals with ALS and 1,264 controls from 5 independent populations, Greenway et al. (2006) confirmed the association between ALS and rs11701. However, the association was observed in Irish and Scottish populations, but not in populations from the U.S., England, or Sweden. Greenway et al. (2006) identified 7 missense mutations in the ANG gene (105850.0001-105850.0007) in 15 individuals, of whom 4 had familial and 11 'sporadic' ALS. Although mutations were present in individuals from all 5 populations, 12 of 15 affected individuals were of Scottish or Irish descent. All patients enrolled in the study had typical ALS, although a higher than expected proportion (60%) of individuals with ANG mutations had bulbar-onset disease. Common haplotypes were observed across the ANG locus and flanking region in Irish and Scottish individuals with K17I (105850.0002) and K40I (105850.0006) mutations, indicative of a founder effect. Greenway et al. (2006) also found a unique shared haplotype for the K17E mutation (105850.0003) in individuals of Swedish and northern Irish ethnicity.

Lambrechts et al. (2003) found ALS at-risk haplotypes in the VEGF (192240) promoter and leader sequence that result in reduced VEGF transcription in the Swedish and English populations with ALS. Although VEGF is a putative modifier of ALS, mutations in that gene had not been found in individuals with ALS. By contrast, the study of Greenway et al. (2006) identified ANG mutations as a clear susceptibility factor for the development of ALS, particularly in individuals of Irish or Scottish descent. The findings provided further evidence that variations in hypoxia-inducible genes have an important role in ALS.

In 4 of 298 unrelated North American patients with ALS, Wu et al. (2007) identified 4 different heterozygous mutations in the ANG gene (see, e.g., 105850.0008-105850.0009), including the previously reported K17I mutation. Functional expression studies showed loss of angiogenic function of all mutant proteins.

Gellera et al. (2008) identified 7 different ANG mutations (see, e.g., 105850.0010) in 9 (1.2%) of 737 Italian patients with ALS. The mutational frequency was higher among patients with familial disease (2.3%) compared to those with sporadic disease (1.0%). Gellera et al. (2008) found no association between ALS and rs11701 in their cohort, which included 515 controls.

Paubel et al. (2008) identified 2 different mutations (see, e.g., 105850.0007) in 3 of 855 French patients with sporadic ALS. They did not observe an association between rs11701 and the disorder in their cohort.

Van Es et al. (2009) identified heterozygosity for the K17I mutation in affected individuals from a 4-generation family with ALS.

Millecamps et al. (2010) identified the K17I mutation in 2 (0.6%) of 162 French probands with familial ALS. Both showed dominant inheritance. However, 1 of the K17I carriers was also found to carry a heterozygous mutation in the FUS gene (R521C; 137070.0004), which causes ALS6 (608030).


REFERENCES

  1. Gellera, C., Colombrita, C., Ticozzi, N., Castellotti, B., Bragato, C., Ratti, A., Taroni, F., Silani, V. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics 9: 33-40, 2008. [PubMed: 18087731, related citations] [Full Text]

  2. Greenway, M. J., Alexander, M. D., Ennis, S., Traynor, B. J., Corr, B., Frost, E., Green, A., Hardiman, O. A novel candidate region for ALS on chromosome 14q11.2. Neurology 63: 1936-1938, 2004. [PubMed: 15557516, related citations] [Full Text]

  3. Greenway, M. J., Andersen, P. M., Russ, C., Ennis, S., Cashman, S., Donaghy, C., Patterson, V., Swingler, R., Kieran, D., Prehn, J., Morrison, K. E., Green, A., Acharya, K. R., Brown, R. H., Jr., Hardiman, O. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nature Genet. 38: 411-413, 2006. [PubMed: 16501576, related citations] [Full Text]

  4. Hayward, C., Colville, S., Swingler, R. J., Brock, D. J. H. Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 52: 1899-1901, 1999. [PubMed: 10371543, related citations] [Full Text]

  5. Lambrechts, D., Storkebaum, E., Morimoto, M., Del-Favero, J., Desmet, F., Marklund, S. L., Wyns, S., Thijs, V., Andersson, J., van Marion, I., Al-Chalabi, A., Bornes, S., and 22 others. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nature Genet. 34: 383-394, 2003. [PubMed: 12847526, related citations] [Full Text]

  6. Millecamps, S., Salachas, F., Cazeneuve, C., Gordon, P., Bricka, B., Camuzat, A., Guillot-Noel, L., Russaouen, O., Bruneteau, G., Pradat, P.-F., Le Forestier, N., Vandenberghe, N., and 14 others. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J. Med. Genet. 47: 554-560, 2010. [PubMed: 20577002, related citations] [Full Text]

  7. Paubel, A., Violette, J., Amy, M., Praline, J., Meininger, V., Camu, W., Corcia, P., Andres, C. R., Vourc'h, P. Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. Arch. Neurol. 65: 1333-1336, 2008. [PubMed: 18852347, related citations] [Full Text]

  8. Van Es, M. A., Diekstra, F. P., Veldink, J. H., Baas, F., Bourque, P. R., Schelhaas, H. J., Strengman, E., Hennekam, E. A. M., Lindhout, D., Ophoff, R. A., van den Berg, L. H. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology 72: 287-288, 2009. Note: Erratum: Neurology 72: 774 only, 2009. [PubMed: 19153377, related citations] [Full Text]

  9. Wu, D., Yu, W., Kishikawa, H., Folkerth, R. D., Iafrate, A. J., Shen, Y., Xin, W., Sims, K., Hu, G. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann. Neurol. 62: 609-617, 2007. [PubMed: 17886298, images, related citations] [Full Text]


Cassandra L. Kniffin - updated : 9/27/2010
Cassandra L. Kniffin - updated : 4/14/2009
Cassandra L. Kniffin - updated : 3/12/2009
Cassandra L. Kniffin - updated : 4/2/2008
Creation Date:
Cassandra L. Kniffin : 3/14/2008
carol : 03/18/2019
alopez : 03/15/2019
carol : 12/08/2011
carol : 2/11/2011
wwang : 9/29/2010
ckniffin : 9/27/2010
wwang : 12/1/2009
ckniffin : 11/13/2009
wwang : 4/28/2009
ckniffin : 4/14/2009
wwang : 3/18/2009
ckniffin : 3/12/2009
wwang : 4/16/2008
ckniffin : 4/2/2008
wwang : 4/2/2008
ckniffin : 3/14/2008

# 611895

AMYOTROPHIC LATERAL SCLEROSIS 9; ALS9


SNOMEDCT: 1204351003;   ORPHA: 803;   DO: 0060200;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
14q11.2 Amyotrophic lateral sclerosis 9 611895 3 ANG 105850

TEXT

A number sign (#) is used with this entry because of evidence that amyotrophic lateral sclerosis-9 (ALS9) is caused by heterozygous mutation in the angiogenin gene (ANG; 105850) on chromosome 14q11.

For a general phenotypic description and a discussion of genetic heterogeneity of amyotrophic lateral sclerosis, see ALS1 (105400).


Clinical Features

Van Es et al. (2009) reported a 4-generation family with autosomal dominant ALS due to ANG mutation. Affected individuals had classic signs of the disorder, including progressive upper and lower motor neuron loss affecting the limbs, but 1 patient presented with parkinsonism and later developed signs of frontotemporal dementia. One obligate carrier did not develop the disease by age 75, indicating incomplete penetrance.


Mapping

Hayward et al. (1999) and Greenway et al. (2004) identified chromosome 14q11.2 as a candidate region for ALS in Irish and Scottish populations.


Molecular Genetics

Greenway et al. (2004) reported an association between ALS and a synonymous SNP in the ANG gene (rs11701) in an Irish population. Among in 1,629 individuals with ALS and 1,264 controls from 5 independent populations, Greenway et al. (2006) confirmed the association between ALS and rs11701. However, the association was observed in Irish and Scottish populations, but not in populations from the U.S., England, or Sweden. Greenway et al. (2006) identified 7 missense mutations in the ANG gene (105850.0001-105850.0007) in 15 individuals, of whom 4 had familial and 11 'sporadic' ALS. Although mutations were present in individuals from all 5 populations, 12 of 15 affected individuals were of Scottish or Irish descent. All patients enrolled in the study had typical ALS, although a higher than expected proportion (60%) of individuals with ANG mutations had bulbar-onset disease. Common haplotypes were observed across the ANG locus and flanking region in Irish and Scottish individuals with K17I (105850.0002) and K40I (105850.0006) mutations, indicative of a founder effect. Greenway et al. (2006) also found a unique shared haplotype for the K17E mutation (105850.0003) in individuals of Swedish and northern Irish ethnicity.

Lambrechts et al. (2003) found ALS at-risk haplotypes in the VEGF (192240) promoter and leader sequence that result in reduced VEGF transcription in the Swedish and English populations with ALS. Although VEGF is a putative modifier of ALS, mutations in that gene had not been found in individuals with ALS. By contrast, the study of Greenway et al. (2006) identified ANG mutations as a clear susceptibility factor for the development of ALS, particularly in individuals of Irish or Scottish descent. The findings provided further evidence that variations in hypoxia-inducible genes have an important role in ALS.

In 4 of 298 unrelated North American patients with ALS, Wu et al. (2007) identified 4 different heterozygous mutations in the ANG gene (see, e.g., 105850.0008-105850.0009), including the previously reported K17I mutation. Functional expression studies showed loss of angiogenic function of all mutant proteins.

Gellera et al. (2008) identified 7 different ANG mutations (see, e.g., 105850.0010) in 9 (1.2%) of 737 Italian patients with ALS. The mutational frequency was higher among patients with familial disease (2.3%) compared to those with sporadic disease (1.0%). Gellera et al. (2008) found no association between ALS and rs11701 in their cohort, which included 515 controls.

Paubel et al. (2008) identified 2 different mutations (see, e.g., 105850.0007) in 3 of 855 French patients with sporadic ALS. They did not observe an association between rs11701 and the disorder in their cohort.

Van Es et al. (2009) identified heterozygosity for the K17I mutation in affected individuals from a 4-generation family with ALS.

Millecamps et al. (2010) identified the K17I mutation in 2 (0.6%) of 162 French probands with familial ALS. Both showed dominant inheritance. However, 1 of the K17I carriers was also found to carry a heterozygous mutation in the FUS gene (R521C; 137070.0004), which causes ALS6 (608030).


REFERENCES

  1. Gellera, C., Colombrita, C., Ticozzi, N., Castellotti, B., Bragato, C., Ratti, A., Taroni, F., Silani, V. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics 9: 33-40, 2008. [PubMed: 18087731] [Full Text: https://doi.org/10.1007/s10048-007-0111-3]

  2. Greenway, M. J., Alexander, M. D., Ennis, S., Traynor, B. J., Corr, B., Frost, E., Green, A., Hardiman, O. A novel candidate region for ALS on chromosome 14q11.2. Neurology 63: 1936-1938, 2004. [PubMed: 15557516] [Full Text: https://doi.org/10.1212/01.wnl.0000144344.39103.f6]

  3. Greenway, M. J., Andersen, P. M., Russ, C., Ennis, S., Cashman, S., Donaghy, C., Patterson, V., Swingler, R., Kieran, D., Prehn, J., Morrison, K. E., Green, A., Acharya, K. R., Brown, R. H., Jr., Hardiman, O. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nature Genet. 38: 411-413, 2006. [PubMed: 16501576] [Full Text: https://doi.org/10.1038/ng1742]

  4. Hayward, C., Colville, S., Swingler, R. J., Brock, D. J. H. Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 52: 1899-1901, 1999. [PubMed: 10371543] [Full Text: https://doi.org/10.1212/wnl.52.9.1899]

  5. Lambrechts, D., Storkebaum, E., Morimoto, M., Del-Favero, J., Desmet, F., Marklund, S. L., Wyns, S., Thijs, V., Andersson, J., van Marion, I., Al-Chalabi, A., Bornes, S., and 22 others. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nature Genet. 34: 383-394, 2003. [PubMed: 12847526] [Full Text: https://doi.org/10.1038/ng1211]

  6. Millecamps, S., Salachas, F., Cazeneuve, C., Gordon, P., Bricka, B., Camuzat, A., Guillot-Noel, L., Russaouen, O., Bruneteau, G., Pradat, P.-F., Le Forestier, N., Vandenberghe, N., and 14 others. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J. Med. Genet. 47: 554-560, 2010. [PubMed: 20577002] [Full Text: https://doi.org/10.1136/jmg.2010.077180]

  7. Paubel, A., Violette, J., Amy, M., Praline, J., Meininger, V., Camu, W., Corcia, P., Andres, C. R., Vourc'h, P. Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. Arch. Neurol. 65: 1333-1336, 2008. [PubMed: 18852347] [Full Text: https://doi.org/10.1001/archneur.65.10.1333]

  8. Van Es, M. A., Diekstra, F. P., Veldink, J. H., Baas, F., Bourque, P. R., Schelhaas, H. J., Strengman, E., Hennekam, E. A. M., Lindhout, D., Ophoff, R. A., van den Berg, L. H. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology 72: 287-288, 2009. Note: Erratum: Neurology 72: 774 only, 2009. [PubMed: 19153377] [Full Text: https://doi.org/10.1212/01.wnl.0000339487.84908.00]

  9. Wu, D., Yu, W., Kishikawa, H., Folkerth, R. D., Iafrate, A. J., Shen, Y., Xin, W., Sims, K., Hu, G. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann. Neurol. 62: 609-617, 2007. [PubMed: 17886298] [Full Text: https://doi.org/10.1002/ana.21221]


Contributors:
Cassandra L. Kniffin - updated : 9/27/2010
Cassandra L. Kniffin - updated : 4/14/2009
Cassandra L. Kniffin - updated : 3/12/2009
Cassandra L. Kniffin - updated : 4/2/2008

Creation Date:
Cassandra L. Kniffin : 3/14/2008

Edit History:
carol : 03/18/2019
alopez : 03/15/2019
carol : 12/08/2011
carol : 2/11/2011
wwang : 9/29/2010
ckniffin : 9/27/2010
wwang : 12/1/2009
ckniffin : 11/13/2009
wwang : 4/28/2009
ckniffin : 4/14/2009
wwang : 3/18/2009
ckniffin : 3/12/2009
wwang : 4/16/2008
ckniffin : 4/2/2008
wwang : 4/2/2008
ckniffin : 3/14/2008